Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.78 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.78 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.78 |
| ▸ | IL2 | P60568 | 13/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zegocractin SCHEMBL29391484 | 0.88 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| Zegocractin SCHEMBL18038390 | 0.88 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| Zegocractin SCHEMBL29362538 | 0.88 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL12241468 | 0.86 | STIM1 (0.80) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL16572605 | 0.85 | STIM1 (0.72) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL1702004 | 0.84 | STIM1 (0.87) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16018198 | 0.83 | STIM1 (0.70) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12155790 | 0.83 | STIM1 (0.76) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL14881300 | 0.82 | STIM1 (0.68) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12155799 | 0.81 | STIM1 (0.69) | STIM1ORAI1ORAI2IL2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013737-B2 | Pyrazine-containing compound | CALCIMEDIA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10973818-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| US-20200253966-A1 | CRAC CHANNEL INHIBITOR COMPOSITIONS | CALCIMEDICA, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253966-A1 | CRAC CHANNEL INHIBITOR COMPOSITIONS | CACNA1C, CACNA1E, IAPP | STIM1 66/4885ORAI1 5/4885ORAI2 21/4885 |
| US-11013737-B2 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885ORAI2 260/4885 |
| US-10973818-B2 | — | IAPP, NFATC1, PLA2R1 | STIM1 183/4885ORAI1 18/4885ORAI2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.